Jan 27, 2023
Sotorasib in Previously Treated Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer: In Conversation With The ASCO Post
On this episode, *Chandrakanth Are, MBBS, MBA, FSSO, FRCS, FACS*, Professor of Surgical Oncology and Global Health at University of Nebraska Medical Center, and an editorial advisor for _The ASCO Post, _holds a conversation with *John H. Strickler, MD*, a medical oncologist at Duke University Medical Center. The topic is the safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients with _KRAS_ G12C–mutated pancreatic cancer, based on Strickler et al’s paper published on January 5th in _The New England Journal of Medicine_.
*Coverage of stories discussed this week on ascopost.com:*
Sotorasib in Previously Treated Patients With _KRAS_ G12C–Mutated Advanced Pancreatic Cancer
To listen to more podcasts from ASCO, visit asco.org/podcasts.